QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:JNCE

Jounce Therapeutics - JNCE Stock Forecast, Price & News

$1.52
+0.04 (+2.70%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.47
$1.54
50-Day Range
$0.90
$1.67
52-Week Range
$0.58
$7.94
Volume
1.29 million shs
Average Volume
2.38 million shs
Market Capitalization
$79.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Jounce Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
294.7% Upside
$6.00 Price Target
Short Interest
Bearish
9.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
-0.23mentions of Jounce Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$65,044 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.01) to ($1.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Medical Sector

226th out of 986 stocks

Biological Products, Except Diagnostic Industry

35th out of 165 stocks


JNCE stock logo

About Jounce Therapeutics (NASDAQ:JNCE) Stock

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Why Jounce Therapeutics Stock Is Moving Higher Today?
Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?
Jounce Shares Bounce Higher on Tie-Up With Redx >JNCE
Raymond James downgrades Jounce Therapeutics (JNCE) to a Hold
Redx and Jounce Announce Recommended Business Combination
See More Headlines
Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Company Calendar

Last Earnings
11/04/2021
Today
3/23/2023
Next Earnings (Estimated)
3/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JNCE
Fax
N/A
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+294.7%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-50,920,000.00
Pretax Margin
-61.93%

Debt

Sales & Book Value

Annual Sales
$82 million
Book Value
$3.54 per share

Miscellaneous

Free Float
48,532,000
Market Cap
$79.25 million
Optionable
Optionable
Beta
0.63

Key Executives

  • Richard Murray
    President, Chief Executive Officer & Director
  • Kimberlee Cobleigh Drapkin
    Chief Financial & Accounting Officer, Treasurer
  • Elizabeth G. TrehuElizabeth G. Trehu
    Chief Medical Officer
  • Dmitri Wiederschain
    Chief Scientific Officer
  • Stephen Farrand
    Chief Technical Officer













JNCE Stock - Frequently Asked Questions

Should I buy or sell Jounce Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" JNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JNCE, but not buy additional shares or sell existing shares.
View JNCE analyst ratings
or view top-rated stocks.

What is Jounce Therapeutics' stock price forecast for 2023?

5 brokerages have issued 1-year price targets for Jounce Therapeutics' stock. Their JNCE share price forecasts range from $3.00 to $11.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 294.7% from the stock's current price.
View analysts price targets for JNCE
or view top-rated stocks among Wall Street analysts.

How have JNCE shares performed in 2023?

Jounce Therapeutics' stock was trading at $1.11 on January 1st, 2023. Since then, JNCE shares have increased by 36.9% and is now trading at $1.52.
View the best growth stocks for 2023 here
.

Are investors shorting Jounce Therapeutics?

Jounce Therapeutics saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 4,170,000 shares, an increase of 202.2% from the February 13th total of 1,380,000 shares. Based on an average trading volume of 2,390,000 shares, the short-interest ratio is presently 1.7 days. Currently, 9.6% of the shares of the company are sold short.
View Jounce Therapeutics' Short Interest
.

When is Jounce Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our JNCE earnings forecast
.

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15. During the same period in the prior year, the company posted ($0.73) earnings per share.

What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?

45 employees have rated Jounce Therapeutics Chief Executive Officer Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among the company's employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jounce Therapeutics own?
When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Bank of America Corp DE (6.34%), Millennium Management LLC (3.54%), Morgan Stanley (3.21%), Dimensional Fund Advisors LP (1.38%), Geode Capital Management LLC (1.30%) and Assenagon Asset Management S.A. (1.01%). Insiders that own company stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kevin C Tang, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third.
View institutional ownership trends
.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $1.52.

How much money does Jounce Therapeutics make?

Jounce Therapeutics (NASDAQ:JNCE) has a market capitalization of $79.25 million and generates $82 million in revenue each year. The company earns $-50,920,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does Jounce Therapeutics have?

The company employs 137 workers across the globe.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.jouncetx.com. The company can be reached via phone at (857) 259-3840 or via email at mdeon@jouncetx.com.

This page (NASDAQ:JNCE) was last updated on 3/23/2023 by MarketBeat.com Staff